Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.42 |
| ▸ | LPL | P06858 | 1/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | AAK1 | Q2M2I8 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22264805 | 0.84 | ALDH2 (0.41) | LIPGLPLHIF1ATSHRALDH1A1 | |
| SCHEMBL22273380 | 0.84 | ALDH2 (0.41) | LIPGLPLHIF1ATSHRALDH1A1 | |
| SCHEMBL18343341 | 0.80 | LIPG (0.44) | LIPGLPLHIF1AROCK1 | |
| SCHEMBL30345408 | 0.77 | AR (0.46) | LIPGLPLHIF1AARAAK1 | |
| SCHEMBL30522347 | 0.76 | KDM4E (0.49) | L3MBTL1TSHRALDH1A1SMN1; SMN2 | |
| SCHEMBL15376138 | 0.76 | LIPG (0.46) | LIPGLPLHIF1AALDH1A1SMN1; SMN2 | |
| SCHEMBL25330897 | 0.76 | LIPG (0.44) | LIPGLPLHIF1AAAK1ROCK1 | |
| SCHEMBL22264963 | 0.76 | CYP1A2 (0.44) | LIPGLPLHIF1ATSHRALDH1A1 | |
| SCHEMBL22264962 | 0.76 | CYP1A2 (0.44) | LIPGLPLHIF1ATSHRALDH1A1 | |
| SCHEMBL25330900 | 0.76 | LIPG (0.44) | LIPGLPLHIF1AAAK1ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3914256-B1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES INC (US) | 2024-05-29 | — | — | EP | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-11773101-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2023-10-03 | — | — | US | disclosed |
| US-20210380590-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
| US-20210380590-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2021-12-09 | — | — | US | disclosed |
| EP-3914256-A1 | GPR35 MODULATORS | Prometheus Biosciences, Inc. (US) | 2021-12-01 | — | — | EP | disclosed |
| CN-113631168-A | GPR35 modulators | 普罗米修斯生物科学公司 | 2021-11-09 | — | — | CN | disclosed |
| US-11053251-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| US-11053251-B2 | GPR35 modulators | PROMETHEUS BIOSCIENCES, INC. (US) | 2021-07-06 | — | — | US | disclosed |
| WO-2020154492-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20200239476-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20200239476-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. | 2020-07-30 | — | — | US | disclosed |
| WO-2020154492-A1 | GPR35 MODULATORS | PROMETHEUS BIOSCIENCES, INC. (US) | 2020-07-30 | — | — | WO | disclosed |
| US-20050234066-A1 | Alpha substituted carboxylic acids | AGOURON PHARMACEUTICALS, INC. | 2005-10-20 | — | — | US | disclosed |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PFIZER INC | 2005-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050234066-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | LIPG 740/4885LPL 251/4885HIF1A 593/4885 |
| US-20210380590-A1 | GPR35 MODULATORS | GPR35, GPR55, GPR65 | LIPG 784/4885LPL 779/4885HIF1A 1357/4885 |
| US-11053251-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | LIPG 784/4885LPL 779/4885HIF1A 1357/4885 |
| US-11773101-B2 | GPR35 modulators | GPR35, GPR55, GPR65 | LIPG 784/4885LPL 779/4885HIF1A 1357/4885 |
| US-20050187266-A1 | Alpha substituted carboxylic acids | PPARG, PPARA, PPARD | LIPG 740/4885LPL 251/4885HIF1A 593/4885 |
| US-20200239476-A1 | GPR35 MODULATORS | GPR35, GPR55, GPR65 | LIPG 784/4885LPL 779/4885HIF1A 1357/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.